Biological and clinical significance of flap endonuclease‑1 in triple‑negative breast cancer: Support of metastasis and a poor prognosis.


Journal

Oncology reports
ISSN: 1791-2431
Titre abrégé: Oncol Rep
Pays: Greece
ID NLM: 9422756

Informations de publication

Date de publication:
12 2020
Historique:
received: 19 03 2020
accepted: 27 07 2020
pubmed: 31 10 2020
medline: 31 7 2021
entrez: 30 10 2020
Statut: ppublish

Résumé

Flap endonuclease‑1 (FEN1), a structure‑specific nuclease participating in DNA replication and repair processes, has been confirmed to promote the proliferation and drug resistance of tumor cells. However, the biological functions of FEN1 in cancer cell migration and invasion have not been defined. In the present study, using online database analysis and immunohistochemistry of the specimens, it was found that FEN1 expression was associated with a highly invasive triple‑negative breast cancer (TNBC) subtype in both breast cancer samples from the Oncomine database and from patients recruited into the study. Furthermore, FEN1 was an important biomarker of lymph node metastasis and poor prognosis in patients with TNBC. FEN1 promoted migration of TNBC cell lines and FEN1 knockdown reduced the number of spontaneous lung metastasis in vivo. Ingenuity Pathway Analysis of FEN1‑related transcripts in 198 patients with TNBC demonstrated that the polo‑like kinase family may be the downstream target of FEN1. PLK4 was further identified as a critical target of FEN1 mediating TNBC cell migration, by regulating actin cytoskeleton rearrangement. The results of the present study validate FEN1 as a therapeutic target in patients with TNBC and revealed a new role for FEN1 in regulating TNBC invasion and metastasis.

Identifiants

pubmed: 33125141
doi: 10.3892/or.2020.7812
pmc: PMC7610327
doi:

Substances chimiques

Biomarkers, Tumor 0
Flap Endonucleases EC 3.1.-
FEN1 protein, human EC 3.1.11.-

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

2443-2454

Références

Nature. 2017 Aug 17;548(7667):297-303
pubmed: 28783718
Annu Rev Biochem. 2013;82:119-38
pubmed: 23451868
Nat Rev Mol Cell Biol. 2014 Jul;15(7):433-52
pubmed: 24954208
BJU Int. 2006 Aug;98(2):445-51
pubmed: 16879693
Pathol Res Pract. 2018 Jun;214(6):840-847
pubmed: 29735403
BMC Cancer. 2007 Jul 24;7:134
pubmed: 17650314
J Cancer. 2019 Oct 21;10(26):6618-6634
pubmed: 31777591
Mol Cancer. 2014 Jun 02;13:136
pubmed: 24885194
J Clin Invest. 2011 Jul;121(7):2750-67
pubmed: 21633166
Cancer Res. 2017 Jan 15;77(2):434-447
pubmed: 27872092
Int J Mol Med. 2014 May;33(5):1268-74
pubmed: 24590400
Life Sci. 2015 Oct 15;139:145-52
pubmed: 26334567
Anticancer Res. 2009 Jul;29(7):2453-9
pubmed: 19596913
DNA Repair (Amst). 2018 Mar;63:1-9
pubmed: 29358095
J Cancer. 2016 Jun 06;7(9):1125-32
pubmed: 27326256
Pathology. 2017 Feb;49(2):156-165
pubmed: 28034453
BMC Cancer. 2015 Feb 13;15:50
pubmed: 25885449
Neoplasia. 2007 Feb;9(2):166-80
pubmed: 17356713
Nat Rev Clin Oncol. 2016 Nov;13(11):674-690
pubmed: 27184417
NPJ Syst Biol Appl. 2018 Oct 24;4:38
pubmed: 30374409
Oncol Lett. 2015 Apr;9(4):1707-1714
pubmed: 25789027
Thorac Cancer. 2017 May;8(3):192-196
pubmed: 28319330
Bioinformatics. 2014 Feb 15;30(4):523-30
pubmed: 24336805
Nature. 2018 Jan 25;553(7689):467-472
pubmed: 29342134
Exp Ther Med. 2017 Oct;14(4):3265-3272
pubmed: 28912877
Am J Pathol. 2018 Jan;188(1):242-251
pubmed: 29037854
Clin Cancer Res. 2007 Aug 1;13(15 Pt 1):4429-34
pubmed: 17671126
Clin Cancer Res. 2005 Jan 15;11(2 Pt 1):473-82
pubmed: 15701830
Oncogene. 2015 Jun;34(26):3441-51
pubmed: 25174401
PLoS One. 2015 Oct 02;10(10):e0139435
pubmed: 26431531
N Engl J Med. 2010 Nov 11;363(20):1938-48
pubmed: 21067385
Mol Oncol. 2014 Oct;8(7):1326-38
pubmed: 24880630
Int J Oncol. 2019 Feb;54(2):479-490
pubmed: 30570110
Cell Death Dis. 2018 Jan 19;9(2):54
pubmed: 29352113
EBioMedicine. 2016 Dec;14:32-43
pubmed: 27852524
Nucleic Acids Res. 2017 Jan 4;45(D1):D777-D783
pubmed: 27899578
Mol Cancer Res. 2008 Nov;6(11):1710-7
pubmed: 19010819
Mol Oncol. 2017 Jun;11(6):640-654
pubmed: 28371273
Oncogene. 2003 Oct 16;22(46):7243-6
pubmed: 14562054
FASEB J. 2019 Oct;33(10):10717-10730
pubmed: 31266372
Cell Cycle. 2015;14(4):544-53
pubmed: 25590559
Mol Med Rep. 2016 Jan;13(1):386-92
pubmed: 26718738
Nat Rev Clin Oncol. 2019 Feb;16(2):81-104
pubmed: 30356138

Auteurs

Lu Xu (L)

Department of Medical Oncology, The First Hospital of China Medical University, Shenyang, Liaoning 110001, P.R. China.

Jing-Lei Qu (JL)

Department of Medical Oncology, The First Hospital of China Medical University, Shenyang, Liaoning 110001, P.R. China.

Na Song (N)

Department of Medical Oncology, The First Hospital of China Medical University, Shenyang, Liaoning 110001, P.R. China.

Ling-Yun Zhang (LY)

Department of Medical Oncology, The First Hospital of China Medical University, Shenyang, Liaoning 110001, P.R. China.

Xue Zeng (X)

Department of Medical Oncology, The First Hospital of China Medical University, Shenyang, Liaoning 110001, P.R. China.

Xiao-Fang Che (XF)

Department of Medical Oncology, The First Hospital of China Medical University, Shenyang, Liaoning 110001, P.R. China.

Ke-Zuo Hou (KZ)

Department of Medical Oncology, The First Hospital of China Medical University, Shenyang, Liaoning 110001, P.R. China.

Sha Shi (S)

Department of Medical Oncology, The First Hospital of China Medical University, Shenyang, Liaoning 110001, P.R. China.

Zu-Ying Feng (ZY)

Boz Life Science Research and Teaching Institute, San Diego, CA 92109, USA.

Xiu-Juan Qu (XJ)

Department of Medical Oncology, The First Hospital of China Medical University, Shenyang, Liaoning 110001, P.R. China.

Yun-Peng Liu (YP)

Department of Medical Oncology, The First Hospital of China Medical University, Shenyang, Liaoning 110001, P.R. China.

Yue-E Teng (YE)

Department of Medical Oncology, The First Hospital of China Medical University, Shenyang, Liaoning 110001, P.R. China.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH